RxDoctor Payments DataLook up a doctor →

Suresh Misra, MD

Family Medicine · Milwaukee, WINPI 1174588768

Payments from drug & device makers

$15,719in general payments, 2019–2025

Across 416 payments — averaging $37.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Boehringer Ingelheim$1K
  • GSK$977
  • Pfizer$951
  • Johnson & Johnson$789
  • Phathom Pharmaceuticals, Inc.$671
  • plus $7K from 37 others

What the payments were for

  • Food & beverage$15,59199%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,719 in reported general payments places this provider in the 95th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$199,690
Medicare patients
173
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban168$140,130
JardianceEmpagliflozin63$62,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$55,811
MyrbetriqMirabegron37$27,885
XareltoRivaroxaban35$23,711
OzempicSemaglutide13$20,956
FarxigaDapagliflozin Propanediol20$17,577
TradjentaLinagliptin15$11,176
Breo ElliptaFluticasone/Vilanterol11$8,324
JanuviaSitagliptin Phosphate13$7,777
Atorvastatin Calcium686$6,083
Pantoprazole Sodium309$3,917
Omeprazole197$3,164
Levothyroxine Sodium338$3,028
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$951$140,130168 claims
Boehringer IngelheimJardiance, Tradjenta$1,449$73,58378 claims
GSKTrelegy Ellipta, Breo Ellipta$977$64,13573 claims
Astellas Pharma US IncMyrbetriq$357$27,88537 claims
Johnson & JohnsonXarelto$789$23,71135 claims
Novo NordiskOzempic$499$20,95613 claims
AstraZenecaFarxiga$3,825$17,57720 claims
MerckJanuvia$354$7,77713 claims
Lilly USA, LLCHumalog$472$1,62922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →